In this webinar Conjoint A/Prof Chee Khoo and Conjoint A/Prof Belinda Cochrane review latest recommendations for COPD management and describe the actions you can take to reduce the impact of comorbid CVD in...
In this webinar, Associate Professor Michael Woodward, Professor Grant Waterer and GP Dr Victoria Hayes explain the risk of respiratory syncytial virus (RSV) in people aged 60 and above
In this clinical audit you will conduct a review of patients with pancreatic exocrine insufficiency (PEI) who are currently receiving PERT (pancreatic enzyme replacement therapy), in order to assess their...
In this clinical audit you will review the management of patients with type 2 diabetes and overweight or obesity.
Review your management of patients with HFrEF (heart failure with reduced ejection fraction) in this clinical audit, and update their treatment to be in line with latest recommendations including the "four...
Liver disease now affects up to 3 of every 10 Australian adults. Primary liver cancer is the most rapidly rising cause of cancer death. Health promotion, prevention, proactive case-finding, early...

Updated management of HFrEF in general practice

[Expert video | Duration: 11:06] With new Australian consensus recommendations and available therapies for heart failure with reduced ejection fraction (HFrEF), GPs now have further options for optimising management of their HFrEF patients. Listen to Dr Chee Khoo discuss the updated recommendations and its implications for clinical practice, in both current and newly diagnosed patients.

The rising health threat of liver disease: What GPs can do to prevent premature mortality

Liver disease now affects up to 3 of every 10 Australian adults. Primary liver cancer is the most rapidly rising cause of cancer death. Health promotion, prevention, proactive case-finding, early identification of progressive liver fibrosis and early treatment of liver diseases are essential to prevent premature mortality. Learn how to identify, manage and support your patients with liver disease.

Dementia risk reduction: Applying the evidence to optimise your patients' brain health - On-demand webinar

In this on-demand webinar, Dr Hilton Koppe, Dr Marita Long and Prof Kaarin Anstey explore the latest evidence to assess dementia risk, and apply the latest clinical guidelines to help prevent or delay the onset of dementia in your patients. Through a case-based approach, the speakers discuss how the MBS-supported 45-49 year health assessment can be utilised as a timely and effective opportunity for conducting a brain health check.

Long-acting injectable buprenorphine for the treatment of opioid dependence

Module 1 of 2: This learning module explores the nature of opioid dependence and the diagnostic criteria for opioid use disorder, then outlines the use of pharmacotherapies in medication assisted treatment of opioid dependence (MATOD) and the benefits of opioid agonist treatment including long-acting injectable buprenorphine (LAIB) products.

Practical use of long-acting injectable buprenorphine for the treatment of opioid dependence

Module 2 of 2: This two-part activity provides education on the various long-acting buprenorphine (LAIB) formulations available in Australia, followed by a practical exercise where the learner goes through the steps of assessing whether a patient is suitable for LAIB treatment, and discusses with them how treatment may help them achieve their goals.

Pages